Drugs / MEB-1170
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05748119 | Nov 2022 → Oct 2023 | — | Mebias Discovery, Inc | Unknown | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-11-29 | Mebias Discovery, Inc | Mebias Discovery Initiates a Phase I Clinical Trial of MEB-1170, a Novel Analgesic Drug Candidate for the Treatment of Pain and Prevention of Opioid Use Disorder mebiasdiscovery.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MEB-1170 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05748119 ↗ |
| Route | Oral | “single and multiple oral doses of MEB-1170” NCT05748119 ↗ |